When metabolic disease rewrites infection biology: Long-term multiorgan consequences of Helicobacter pylori infection in diabetes

Table 1 Summary of key experimental findings in Yang et al[1] and their mechanistic and clinical interpretation

Experimental domain	Key finding	Proposed mechanism	Clinical implication
Gastric colonization	Prolonged H. pylori persistence in diabetic mice vs controls	Hyperglycemia impairs mucosal immunity, Th1/Th17 responses, and antimicrobial peptide expression	Diabetic patients may require extended or repeated eradication regimens
Gastric histopathology	Progressive submucosal inflammation and fibrosis; irreversible gastritis	Sustained IL-6, TNF-α, IL-1β release; oxidative stress-driven fibrogenesis	Early eradication essential before irreversible mucosal remodelling
Hepatic virulence factor detection	CagA and other virulence proteins detected in liver tissue	Exosome-mediated systemic CagA delivery; intestinal barrier disruption facilitating portal translocation	H. pylori may contribute to NAFLD/NASH progression in diabetic hosts
Gut microbiota	Compounded dysbiosis; delayed microbial recovery even after bacterial decline	Synergistic disruption of microbial ecology and colonization resistance by H. pylori plus diabetes	Microbiota-targeted adjunctive therapy (probiotics/prebiotics) may benefit diabetic H. pylori patients
Apoptosis profile	Widespread apoptosis across stomach, pancreas, liver, and kidney	Convergence of metabolic stress, immune activation, and pathogen-derived pro-apoptotic signals	Organ function monitoring warranted even after eradication in long-standing diabetic infection
Temporal dissociation	Tissue injury persists despite declining bacterial burden and partial glycemic recovery	Inflammatory memory and self-sustaining cytokine loops operating independently of active infection	Microbiological eradication does not equal biological resolution; post-eradication surveillance is essential

NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; TNF-α: Tumour necrosis factor-alpha; H. pylori: Helicobacter pylori; IL-6: Interleukin-6; IL-1β: Interleukin-1 beta; CagA: Cytotoxin-associated gene A.

Table 2 Comparison of animal models for studying Helicobacter pylori infection in the context of metabolic disease

Model	Metabolic phenotype	Strengths	Limitations	Suitability for H. pylori co-infection
Low-dose STZ mouse (current study)	Insulin deficiency; hyperglycemia	Reproducible; reversible beta-cell injury; established protocol; long-duration follow-up feasible	Models T1DM physiology; lacks insulin resistance; potential direct STZ organ toxicity	High-established for long-term H. pylori co-infection studies
High-fat diet mouse	Insulin resistance; obesity; T2DM-like	Mimics T2DM pathophysiology; relevant inflammatory milieu; models diet-microbiota interaction	Variable hyperglycemia; strain-dependent; more complex to manage	Moderate-underutilized in H. pylori infection research; high priority for future studies
Db/db mouse (leptin receptor deficient)	Severe obesity; insulin resistance; hyperglycemia	Strong metabolic phenotype; spontaneous diabetes; immune dysregulation	Immune defects may confound infection response; expensive; limited vendor availability	Moderate-potential for severe T2DM and H. pylori interaction studies
Mongolian gerbil	Standard (non-diabetic) unless combined with HFD	Natural H. pylori colonization; gastric pathology closely mirrors human disease	Limited genetic tools; poorly validated metabolic disease protocols	Low-metabolic co-disease protocols not established; requires development
Non-human primate	Diet-inducible; closest to human pathophysiology	Highest translational relevance; natural H. pylori susceptibility; full immune system	Prohibitive cost; ethical constraints; long study duration; limited research use	Aspirational-for validation of high-priority mechanistic findings only

STZ: Streptozotocin; T1DM: Type 1 diabetes mellitus; T2DM: Type 2 diabetes mellitus; HFD: High-fat diet; H. pylori: Helicobacter pylori.

Table 3 Controversies and unanswered questions in the field of Helicobacter pylori infection and diabetes mellitus

Controversy/question	Current evidence (for)	Current evidence (against/Limitations)	Research priority
Does H. pylori cause T2DM or is the association confounded?	Meta-analyses show increased T2DM risk with H. pylori infection[11-13]; eradication improves glycemic markers in some RCTs	Confounding by socioeconomic status, diet, obesity; bidirectional causality plausible	Mendelian randomization studies with large biobanks; long-term eradication RCTs with glycemic endpoints
Is hepatic virulence factor detection artefactual?	Exosome-mediated CagA delivery demonstrated in vitro[29]; NAFLD meta-analysis supports association[36]	Tissue contamination possible; causal pathway not fully established in vivo in humans	In vivo tracing studies with fluorescently tagged OMVs; human liver biopsy studies in H. pylori-positive diabetics
Does eradication reverse microbiota disruption?	Short-term restoration of some taxa post-eradication[43,44]; SCFA producers may recover	Antibiotic-associated dysbiosis may worsen microbiota short term; long-term data lacking	Longitudinal microbiome studies pre- and post-eradication in diabetic cohorts, with and without probiotics
Is the STZ model adequate to model T2DM-H. pylori interaction?	Validated platform for metabolic complications; reproducible hyperglycemia; feasible for mechanism discovery	Models T1DM physiology; lacks insulin resistance component; different inflammatory landscape from T2DM	High-fat diet, db/db, or ob/ob mouse models of H. pylori infection are needed for T2DM-relevant data
Therapeutic time window: When is eradication most effective?	Early eradication in H. pylori-positive T2DM patients associated with improved insulin sensitivity[48,49]	No RCT defines optimal timing relative to diabetes duration or infection stage	Staged RCTs stratifying by duration of diabetes and infection at time of eradication

T2DM: Type 2 diabetes mellitus; RCT: Randomized controlled trial; OMV: Outer membrane vesicle; SCFA: Short-chain fatty acid; NAFLD: Non-alcoholic fatty liver disease; STZ: Streptozotocin; T1DM: Type 1 diabetes mellitus; H. pylori: Helicobacter pylori; CagA: Cytotoxin-associated gene A.